


Efficacy and safety of switching to dolutegravir/lamivudine dual therapy from bictegravir/emtricitabine/tenofovir alafenamide among virally suppressed older adults ≥ 60 years: week 24 results from the Sungura study

Loice Achieng Ombajo^{1,2}, Jeremy Penner^{2,3}, Joseph Nkuranga^{1,2}, Victor Omodi^{1,2}, Edwin Otieno^{1,2}, Michelle Kisare⁴, Simon Wahome⁵, Florentius Ndinya⁶, Carolyn Wafula⁶ For the Sungura study group

1. Department of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, Kenya; 2.Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya;


BACKGROUND

- Dolutegravir/lamivudine (DTG/3TC) has demonstrated similar efficacy to three-drug regimens among people without prior virological failure.
- DTG/3TC minimizes exposure to NRTIs which is particularly relevant for older adults, due to age-related comorbidities and increased likelihood of polypharmacy and drug-drug interactions
- DTG/3TC may also potentially cost less than three drug regimens.
- We evaluated the efficacy and safety of switching older adults from bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) to DTG/3TC




METHODS

- The Sungura Study (NCT06444620) is an open-label, single arm, 96-week study conducted at two sites in Kenya
- Eligible participants were adults ≥ 60 years with HIV-1 viral load < 50 copies/mL on B/F/TAF with no prior virological failure and hepatitis B negative
- All were switched to DTG/3TC at enrollment
- The primary endpoint is the proportion of participants with viral load ≥ 50 copies/mL at 48 weeks using the FDA snapshot algorithm
- We present the study's week 24 results



RESULTS

- Between Jul and Sep 2024, 197 participants enrolled in the Sungura Study




RESULTS contd...

- All participants were black African, 49% female and median age 66 years (range 62 to 81)
- Baseline prevalence of comorbidities was high

Characteristic	Total (n=197)
Age (years); median (min, max)	66 (62, 81)
Female Sex	97 (49%)
Time on ART (years)	12.0 (9.5,12.5)
Hypertension	138 (70%)
Impaired fasting glucose or diabetes mellitus	32 (16%)
Dyslipidemia	46 (23%)
Grade 3 creatinine clearance abnormality	61 (31%)
Body-mass index category (kg/m ²)	
Underweight (< 18.5)	5 (2%)
Normal (18.5-24.9)	79 (40%)
Overweight (25.0-29.9)	67 (34%)
Obese (≥ 30)	46 (23%)
ASCVD 10-year predicted risk score category	
Low risk ($< 5.0\%$)	1 (0.5%)
Borderline risk (5.0-7.4%)	20 (11%)
Intermediate risk (7.5-19.9%)	127 (65%)
High risk ($\geq 20\%$)	45 (24%)

- At week 24, all participants remained on DTG/3TC and none (0/197) had HIV viral load ≥ 50 copies/mL



- The median change in weight was +0.5kg (IQR -0.2 to 0.5) with 31 (15.8%) participants having $\geq 5\%$ weight gain
- The median change in 10-year ASCVD risk score was +0.6% (IQR -1.9 to 4.1)

CONCLUSION

- At week 24, there were no incidences of virological failure and no withdrawals from the Sungura study
- Comorbidities were common, highlighting additional considerations for selecting antiretroviral agents for older populations

ACKNOWLEDGEMENT

This is an investigator-initiated trial funded by ViiV Healthcare and sponsored by the University of Nairobi. We would like to thank the study participants, study sites and personnel at Jaramogi Oginga Odinga Teaching and Referral Hospital and the Kenyatta National Hospital, and the Ministry of Health through the National AIDS and STI Control Program

CONTACT

loisea@uonbi.ac.ke

Disclaimer

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.